Noopept (Omberacetam): Clinical Overview and US Status

Noopept, also called omberacetam and chemically N-phenylacetyl-L-prolylglycine ethyl ester, is a synthetic dipeptide nootropic developed in Russia, where it is a registered prescription medication. In the United States it is widely sold online as a nootropic supplement, and its regulatory position there is not what its marketing implies.

This guide situates Noopept within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What Noopept is

Noopept is a small synthetic dipeptide, developed at the Russian Academy of Medical Sciences and structurally related to the racetam family, though it is a dipeptide rather than a true racetam.

It is orally active, which distinguishes it from most peptides and reflects its small size and modified structure. It is used at low milligram doses, considerably lower than piracetam and related compounds.

In Russia and some neighbouring countries it is a registered medication with approved indications relating to cognitive impairment and asthenic conditions. That registration is under a different regulatory system with different evidentiary requirements than the FDA applies.

Proposed mechanisms

Several mechanisms have been proposed. The most cited is upregulation of BDNF and NGF — brain-derived neurotrophic factor and nerve growth factor — in the hippocampus, which would plausibly support synaptic plasticity and memory processes.

Additional proposed actions include antioxidant effects, modulation of glutamatergic and cholinergic signalling, and an active metabolite resembling cycloprolylglycine, an endogenous neuropeptide.

It is worth noting that neurotrophic upregulation is proposed for a great many nootropic compounds, and that measuring BDNF changes in rodent hippocampus is a considerable distance from demonstrating cognitive benefit in humans.

What the evidence contains

The clinical literature is concentrated in Russian-language publications from the originating research environment, examining cognitive and asthenic conditions. Reported findings include improvements in cognitive and mood measures in various patient populations.

The limitations parallel those described for the peptide bioregulators: limited independent replication outside the originating system, restricted accessibility of full trial methodology to external reviewers, and modest study sizes.

There is no substantial body of independent randomized controlled trial evidence in healthy adults supporting the cognitive enhancement claims made in consumer marketing. Most nootropic products, including this one, are sold on mechanism and user report rather than on demonstrated cognitive outcomes.

Reported dosing

These come from published trial protocols. None are available through a US compounding pharmacy. The figures below are taught by Dr. Joseph B. Beavers, MD in Empire’s peptide certification, and are reproduced with his framing intact. Dr. Beavers’ note: Noopept figures come from clinical use in a single country.

United States regulatory status

Noopept is not an FDA-approved drug in the United States. More specifically, the FDA has taken the position that it does not meet the statutory definition of a dietary ingredient, meaning products marketed as dietary supplements containing it are not lawfully marketed as such.

This is a meaningful distinction that consumers rarely appreciate. Being sold openly online as a supplement does not establish that a substance lawfully qualifies as one. The category of foreign prescription medications marketed in the US as nootropic supplements is a recognized regulatory problem.

Practical consequences follow. Products in this space carry the usual concerns about identity, purity and dose accuracy, without the manufacturing oversight applying to either approved drugs or lawfully marketed supplements.

For patients concerned about cognition, the appropriate route is evaluation of contributing factors — sleep, mood, medication effects, vascular risk, thyroid and metabolic status — rather than an unapproved compound of contested legal status. Our peptide formulary lists current status for every agent.